Voir toutes les langues
Identifiant d'origine
QT52
Libellé préféré
évènement indésirable
adverse event Libellé catégorie
Evènements indésirables & pharmacovigilanceAdverse event & pharmacovigilanceMots-clés supplémentaires Q-Code
effet indésirablepharmacovigilanceadverse event reportingCritical Incident Reporting System pharmacovigilanceAcronyme Q-Code
EIEIAEIASAECIRSAcronyme CISMeF
AENote de contenu Q-Code
Événement indésirable ; un évènement traumatisant liée à la gestion médicale, différent des complications d'une maladie (WHO Upssala, 2011). Pharmacovigilance; La détection des effets secondaires à long et court terme de médicaments conventionnels et traditionnels par la recherche, l'exploration de données, le suivi et l'évaluation des informations de santé obtenues auprès des dispensateurs de soins de santé et les patients. (MeSH)Adverse event ; an adverse event is any untoward medical occurrence that may present during treatment with a pharmaceutical product, but which does not necessarily have a causal relationship with this treatment. (WHO Upssala, 2011)
Pharmacovigilance ; The detection of long and short term side effects of conventional and traditional medicines through research, data mining, monitoring, and evaluation of healthcare information obtained from healthcare providers and patients.(MeSH)Contenu conceptuel Q-Code
Adverse effects ; [Subheading] Used with drugs, chemicals, or biological agents in accepted dosage - or with physical agents or manufactured products in normal usage - when intended for diagnostic, therapeutic, prophylactic, or anesthetic purposes. It is used also for adverse effects or complications of diagnostic, therapeutic, prophylactic, anesthetic, surgical, or other procedures, but excludes contraindications for which "contraindications" is used.(MeSH)Adverse event (AE): a medically undesirable event occurring in a research subject, such as an abnormal sign, symptom, worsening of a disease, injury, etc. A serious adverse event (SAE) results in death, hospitalization (or increased hospital stay), persistent disability, birth defect, or any other outcome that seriously jeopardizes the subject’s health. AEs which are also unanticipated problems should be reported promptly to institutional review boards and other appropriate officials. (NIEH gloss)Adverse event; An injury related to medical management, in contrast to complications of disease. Medical management includes all aspects of care, including diagnosis and treatment, failure to diagnose or treat, and the systems and equipment used to deliver care. Adverse events may be preventable or non-preventable (WHO 2005)Adverse outcome pathways ; Models connecting initiating events at the cellular and molecular level to population-wide impacts. Computational models may be at levels relating toxicology to adverse effects.(MeSH 2018)Drug Eruptions Adverse ; cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.(MeSH)Drug-Related Side Effects and Adverse Reactions ; Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals (MeSH)Long Term Adverse Effects ; Persistent detrimental effects from treatment for a condition. Included are effects from surgery such as POSTOPERATIVE COMPLICATIONS, and from DRUG THERAPY, such as CHEMICALLY INDUCED DISORDERS, or other THERAPEUTICS. Failure to attain a desired outcome from treatment for the condition is not considered an adverse effect.(MeSH2016)Nocebo Effect ; An adverse effect occurring with a medical treatment that is not attributable to the actions of the treatment.(MeSH)Pharmacovigilance ;The detection of long and short term side effects of conventional and traditional medicines through research, data mining, monitoring, and evaluation of healthcare information obtained from healthcare providers and patients.(MeSH)Potentially Inappropriate Medication List A list, criteria, or screening tool designed to improve PATIENT SAFETY by determining an individual's exposure to potentially inappropriate drugs. They are designed to prevent MEDICATION ERRORS by INAPPROPRIATE PRESCRIBING. Analysis for a list includes factors such as DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; AGE FACTORS; GENDER; and existing medical conditions.(MeSH)Safety-Based Drug Withdrawals Removal of a drug from the market due to the identification of an intrinsic property of the drug that results in a serious risk to public health.(MeSH)Référence bibliographique
Citation
Birtwhistle RV. Canadian Primary Care Sentinel Surveillance Network: a developing resource for family medicine and public health. Canadian family physician Médecin de famille canadien. 2011; 57(10): 1219-20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21998241
Bracchi RC, Houghton J, Woods FJ, Thomas S, Smail SA, Routledge PA. A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme. British journal of clinical pharmacology. 2005; 60(2): 221-3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16042677
Carson-Stevens A, Hibbert P, Avery A, Butlin A, Carter B, Cooper A, Evans HP, Gibson R, Luff D, Makeham M, McEnhill P, Panesar SS, Parry G, Rees P, Shiels E, Sheikh A, Ward HO, Williams H, Wood F, Donaldson L, Edwards A. A cross-sectional mixed methods study protocol to generate learning from patient safety incidents reported from general practice. BMJ open. 2015; 5(12): e009079. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26628526
Fernald DH, Pace WD, Harris DM, West DR, Main DS, Westfall JM. Event reporting to a primary care patient safety reporting system: a report from the ASIPS collaborative. Annals of family medicine. 2004; 2(4): 327-32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15335131
Golder S, Loke YK, Wright K, Norman G. Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review. PLoS medicine [Internet]. 2016;13(9):1/22. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27649528
Hakkarainen KM, Gyllensten H, Jönsson AK, Andersson Sundell K, Petzold M, Hägg S. Prevalence, nature and potential preventability of adverse drug events - a population-based medical record study of 4970 adults. British journal of clinical pharmacology. 2014; 78(1): 170-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24372506
Hopf YM, Francis J, Helms PJ, Haughney J, Bond C. Linking NHS data for pediatric pharmacovigilance: Results of a Delphi survey. Research in social & administrative pharmacy : RSAP. 2016; 12(2): 267-80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26228658
Keriel-Gascou M, Brami J, Chanelière M, Haeringer-Cholet A, Larrieu C, Villebrun F, Robert T, Michel P. [Which definition and taxonomy of incident to use for a French reporting system in primary care settings?]. Revue d'épidémiologie et de santé publique. 2014; 62(1): 41-52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24439084
Pham JC, Gianci S, Battles J, Beard P, Clarke JR, Coates H, Donaldson L, Eldridge N, Fletcher M, Goeschel CA, Heitmiller E, Hensen J, Kelley E, Loeb J, Runciman W, Sheridan S, Wu AW, Pronovost PJ. Establishing a global learning community for incident-reporting systems. Quality & safety in health care. 2010; 19(5): 446-51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20977995
Woolf SH, Kuzel AJ, Dovey SM, Phillips RL. A string of mistakes: the importance of cascade analysis in describing, counting, and preventing medical errors. Annals of family medicine. 2004; 2(4): 317-26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15335130
Lien BabelNet